Related Experiment Video
Updated: May 13, 2026
Synthesis of pH Dependent Pyrazole, Imidazole, and Isoindolone Dipyrrinone Fluorophores using a Claisen-Schmidt Condensation Approach
Published on: June 10, 2021
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate
Pradip Ghosh1, Jiawei Zhang2, Zheng-Zheng Shi3
1The University of Texas Health Science Center at Houston, The Brown Foundation Institute of Molecular Medicine, Center for Molecular Imaging, Houston, TX 77030, USA.
Abstract:
The murine double minute (MDM2) oncogene a negative regulator of protein 53 (p53) tumor suppressor, is found overexpressed in many different types of cancer and the interaction between MDM2 and p53 has become the target of intensive research. MDM2 inhibitors represent a promising class of p53 activating compounds that may be effective in cancer treatment and diagnostic imaging. Nutlins, a family of cis-imidazoline analogues and small-molecule MDM2 antagonists, have the potential use in cancer therapies. We have synthesized an imidazole derivative (Nutlin-Glycine) conjugated to the commonly used fluorophore, 6-carboxyfluorescein (FAM) and evaluated its possible use as an imaging agent. Cellular uptake studies demonstrated that the fluorescence intensity in human osteosarcoma (SJSA-1) and colon carcinoma (HCT116) cells were significantly increased with the treatment of Nutlin-Glycine-FAM when compared with FAM (control). Blocking studies also confirmed that our imidazole-fluorescein conjugate may be a good candidate for imaging tumors, suggesting the need for further in vivo evaluation by positron emission tomography.
Insights
Researchers developed a novel imaging agent, Nutlin-Glycine-FAM, targeting the MDM2 oncogene. This compound shows promise for cancer imaging by enhancing fluorescence in cancer cells, indicating potential for tumor detection.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The murine double minute (MDM2) oncogene negatively regulates the p53 tumor suppressor protein.
- MDM2 overexpression is common in various cancers, making the MDM2-p53 interaction a key therapeutic and diagnostic target.
- MDM2 inhibitors, like Nutlins, activate p53 and are explored for cancer treatment and imaging.
Purpose of the Study:
- To synthesize and evaluate an imidazole derivative (Nutlin-Glycine) conjugated to 6-carboxyfluorescein (FAM) as a potential cancer imaging agent.
- To assess the cellular uptake and fluorescence properties of the novel conjugate in cancer cell lines.
Main Methods:
- Synthesis of an imidazole derivative (Nutlin-Glycine) conjugated to the fluorophore FAM.
- Cellular uptake studies using human osteosarcoma (SJSA-1) and colon carcinoma (HCT116) cell lines.
- Comparison of fluorescence intensity between Nutlin-Glycine-FAM and FAM (control).
- Blocking studies to confirm target engagement and specificity.
Main Results:
- Nutlin-Glycine-FAM treatment significantly increased fluorescence intensity in SJSA-1 and HCT116 cells compared to FAM alone.
- Blocking studies supported the potential of the imidazole-fluorescein conjugate for tumor imaging.
- The conjugate demonstrated effective cellular uptake in cancer cells.
Conclusions:
- The synthesized Nutlin-Glycine-FAM conjugate shows potential as a novel imaging agent for MDM2-overexpressing tumors.
- Further in vivo evaluation using positron emission tomography is warranted to explore its full diagnostic capabilities.
